Email Contact Phone Company Visit Website

Location Office

Kungsgatan 36
Stockholm
SE

NASDAQ OMX New York Head Office

One Liberty Plaza
New York
NY
US

NASDAQ OMX Stockholm Office

Tullvaktsvägen 15
Stockholm
SE

NASDAQ OMX Rockville Office

805 King Farm Boulevard 1st and 2nd floor
Rockville
MD
US

NASDAQ OMX London Office

Woolgate Exchange, 25 Basinghall Street, City of London
London
GB

NASDAQ OMX New York Office

Marketsite 4 Times Square
New York
NY
US

NASDAQ OMX Hong Kong Office

Room 1207-8, 12/F Man Yee Building 68 Des Voeux Road Central Hong Kong
Hong Kong
HK

NASDAQ OMX Singapore Office

20 Collyer Quay, #17-01
Singapore
SG

NASDAQ OMX Chicago Office

One North Wacker Drive Suite 3600
Chicago
IL
US

NASDAQ OMX Belgium Office

Avenue de Cortenbergh 116
Brussels
BE

NASDAQ OMX Dubai Office

Dubai World Trade Centre Sheikh Zayed Road
Dubai
AE

NASDAQ OMX Tokyo Office

1F, Kojimachi Square Building Nibancho, 3 Chiyoda-ku, Tokyo
Tokyo
JP

NASDAQ OMX Boston Office

100 Franklin St
Boston
MA
US

Location Office

Level 17-19, 110 Bishopsgate
London
GB

Telephone

212 231 5018

Contact

Todd A Swearingen
[email protected]
Back to all NASDAQ OMX announcements

NASDAQ OMX Helsinki Welcomes Herantis Pharma Plc to the First North Market

NASDAQ OMX (NASDAQ: NDAQ) announced that trading in Herantis Pharma Plc (HRTIS) shares commenced today on First North Finland. The company belongs to the Health Care sector. First North Finland is a Multilateral Trading Facility (MTF) aimed towards emerging growth companies and has been operated by NASDAQ OMX Helsinki since April 4, 2011.

Herantis Pharma Plc is a pharmaceutical company specialised in advancing scientific research into clinical research aiming at developing new drugs. The company focuses on diseases with an unmet clinical need. These diseases include for example dry eye syndrome, Parkinson’s disease, and secondary lymphedema. 

Pekka Simula, CEO of Herantis Pharma Plc, commented: ”The First North listing was an optimal way to raise funding for our product pipeline. It’s been 14 years since the last IPO of a drug development company in Finland - we hope that our success encourages others to follow.”

Lauri Rosendahl, President of NASDAQ OMX Helsinki, said: “We welcome Herantis Pharma Plc to First North and to our Health Care sector. Herantis Pharma Plc is a great example of an innovative growth company that is utilizing our First North platform to achieve increased investor exposure and awareness. We look forward to a long-standing partnership with the company and its shareholders.”

Herantis Pharma Plc has appointed UB Capital Oy as Certified Adviser.